Figure 1.
The effects of bortezomib on survival of EBV+T- or NK-cell lines. (A) EBV+ T- or NK-cell lines, SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 48 hours, and the viable cell number was estimated using the XTT assay and expressed in arbitrary units. EBV− T- or NK-cell lines, Jurkat, and KHYG1 cells, respectively, were used as negative controls. The data represent the mean plus or minus standard deviation (SD) of 3 independent experiments. The number of viable cells of SNT8, SNT15, SNT16, and SNK6 were compared with those of EBV− cell lines, Jurkat (*) and KHYG1 (**), treated with the same concentration of bortezomib (P < .05). (B) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 48 hours and used for the assay. Cells were stained with Annexin V and propidium iodide (PI), then analyzed by flow cytometry.

The effects of bortezomib on survival of EBV+T- or NK-cell lines. (A) EBV+ T- or NK-cell lines, SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 48 hours, and the viable cell number was estimated using the XTT assay and expressed in arbitrary units. EBV− T- or NK-cell lines, Jurkat, and KHYG1 cells, respectively, were used as negative controls. The data represent the mean plus or minus standard deviation (SD) of 3 independent experiments. The number of viable cells of SNT8, SNT15, SNT16, and SNK6 were compared with those of EBV− cell lines, Jurkat (*) and KHYG1 (**), treated with the same concentration of bortezomib (P < .05). (B) SNT8, SNT15, SNT16, and SNK6 cells were treated with bortezomib for 48 hours and used for the assay. Cells were stained with Annexin V and propidium iodide (PI), then analyzed by flow cytometry.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal